The Spectranetics Corp

The Spectranetics — Spectranetics — Technical Presentation (August 2016)

21 slides from The Spectranetics's technical presentation, Aug 11, 2016

  1. Slide 1: ILLUMENATE European Randomized Clinical Trial: 12-Month Final Results for the Stellarex DCB

    ILLUMENATE European Randomized Clinical Trial: Prof. Dr. Marianne Brodmann 12-Month Final Results for the Stellarex DCB Division of Angiology, Medical University Graz, Austria On behalf of Dr. Henrik Schröder Jewish Hospital, Berlin, Germany

  2. Slide 2: Disclosures

    Disclosures • Consulting/Honoraria for – Medtronic – BARD – Spectranetics – Intact Vascular – Avinger – Soundbite Medical – Rexgenero – Biotronik – Bayer – Daiichi – Böhringer Ingelheim – Astra Zeneca

  3. Slide 3: ILLUMENATE EU RCT Overview

    ILLUMENATE EU RCT Overview  Stellarex DCB vs. PTA  Prospective, randomized, multi-center, trial  Patients will be followed for up to 5 years  Rigorous data collection process, independent adjudication by: • Angiographic Core Laboratory1 • Duplex Ultrasound Core Laboratory2 • Clinical Events Comm

  4. Slide 4: Investigators

    ILLUMENATE EU RCT Investigators Dr. Henrik Schroeder :Jewish Hospital, Berlin National Principal Investigator Prof. Marianne Brodmann: LKH University Hospital Graz Dr. Beata Lux: St Joseph Hospital, Berlin Prof. Peter Reimer:Clinical Center, Karlsruhe Dr. Dirk-Roelfs Meyer: Lutheran Hospital Hubertu

  5. Slide 5: Objective and Primary Endpoints

    Objective and Primary Endpoints ILLUMENATE EU RCT Objective: Demonstrate safety and efficacy of the Stellarex DCB vs. standard PTA for treatment of arterial disease in the SFA and/or popliteal arteries Primary Safety Endpoint: Freedom from device- and procedure- related death through 30 days and fre

  6. Slide 6: Study Device: Stellarex DCB (Spectranetics)

    Study Device: StellarexTM DCB (Spectranetics) CAUTION: Investigational device. Not for sale or distribution in the United States. EnduraCoatTM technology: • Low dose paclitaxel, 2 µg/mm2 • Excipient: Polyethylene Glycol (PEG) • Proprietary open-folded coating technology Balloon catheter features: •

  7. Slide 7: Key Eligibility Criteria

    Key Eligibility Criteria ILLUMENATE EU RCT Inclusion Criteria • Rutherford class 2, 3 or 4 • Lesion(s) located in the SFA and/or popliteal • Has at least one patent run-off below-the-knee • 1 or 2 target lesion(s) with cumulative length 3-20 cm • Target vessel reference diameter 4-6 mm Exclusion Cri

  8. Slide 8: Trial Design

    ILLUMENATE EU RCT Trial Design Patient Eligible & Consented Pre-dilatation N=328 Stent required (N=33) (BMS + Stellarex) Stent not required (N=295) Randomization (3:1) Stellarex DCB (N=222) PTA (N=72) Provisional stenting as required Post-dilatation as required Provisional stenting as required Post-

  9. Slide 9: Baseline Patient Characteristics

    Baseline Patient Characteristics ILLUMENATE EU RCT ITT data set Stellarex PTA p Age (years) 66.8 ± 9.2 (222) 69.0 ± 8.6 (72) 0.079 Male 72.1% (160/222) 68.1% (49/72) 0.514 Rutherford Clinical Category 0.525 2 15.4% (34/221) 21.1% (15/71) 3 82.8% (183/221) 77.5% (55/71) 4 1.8% (4/221) 1.4% (1/71) Dia

  10. Slide 10: Baseline Angiographic Data

    Baseline Angiographic Data ILLUMENATE EU RCT ITT Data Set: Per Core Lab Stellarex PTA p Lesion Length (cm)1 7.2± 5.2 (250) 7.1 ± 5.3 (79) 0.878 Lesion Type De Novo Restenotic 92.1% (234/254) 7.9% (20/254) 89.9% (71/79) 10.1% (8/79) 0.529 Total Occlusion 19.2% (48/250) 19.0% (15/79) 0.967 Calcificati

  11. Slide 11: Procedural Characteristics

    Procedural Characteristics ILLUMENATE EU RCT ITT data set Stellarex PTA p Pre-dilatation Performed1 100% (254/254) 98.7% (78/79) 0.237 Post-DCB/PTA Dissection Grades Grade A-C Grade D-F 61.1% (151/247) 1.2% (3/247) 74.0% (57/77) 0.0% (0/77) 0.095 Flow-limiting Dissection 0.4% (1/247) 0.0% (0/77) 1.0

  12. Slide 12: Primary Safety Endpoint Met

    Primary Safety Endpoint Met ILLUMENATE EU RCT As-Treated Data Set 1. Composite of freedom from device and procedure-related death through 30 days & freedom from target limb major amputation & CD-TLR through 395 days. Per subject, as adjudicated by the CEC. 2. Numbers are % (n/N) [Events]- Denominato

  13. Slide 13: Key Safety Outcomes

    Key Safety Outcomes ILLUMENATE EU RCT As-Treated Data Set Stellarex PTA P2 12-Month MAEs1 6.8% (14/207) [20] 18.0% (11/61) [12] 0.008 Cardiovascular Death 1.0% (2/206) [3] 1.6% (1/61) [1] 0.542 Target Limb Amputation 0.5% (1/204) [1]3 0.0% (0/60) [0] >0.999 Clinically-Driven TLR 5.9% (12/205) [16] 1

  14. Slide 14: Primary Efficacy Endpoint Met

    Primary Efficacy Endpoint Met ILLUMENATE EU RCT Stellarex PTA Difference [95% CI] P-value Primary Patency at 12 months1 ITT Data Set 83.9% (188/224) [78.5, 88.5] 60.6% (40/66) [47.8, 72.4] 23.3% [10.6%, 36.1%] P<0.001 As-Treated Data Set 83.9% (188/224) [78.5, 88.5] 61.5% (40/65) [48.6, 73.3] 22.4%

  15. Slide 15: Primary Patency at 12 Months

    Primary Patency at 12 Months: 89.0% ILLUMENATE EU RCT ITT Data Set P<0.001 by log-rank test 65.0% @ day 365 Primary patency is defined as freedom from restenosis (determined by duplex ultrasound PSVR threshold of 2.5) and freedom from clinically-driven TLR at 12 months. Assessed per lesion. KM estim

  16. Slide 16: CD-TLR Free at 12 Months

    CD-TLR1 Free at 12 Months: 94.8% ILLUMENATE EU RCT ITT3 Data Set 1. Clinically-driven TLR defined as reintervention due to PSVR≥2.5 (or >50% stenosis via angio) due to an increase in the RCC >1 category or deterioration in the ABI by >0.15 compared to maximum early post-procedural level. Per subject

  17. Slide 17: Key Secondary Endpoints

    Key Secondary Endpoints ILLUMENATE EU RCT ITT Data Set Percent of Subjects with Improvements at 12 Months vs. Baseline  Similar outcomes at 12 months, with almost 3x greater rate of reintervention in the PTA arm.1 1. CD-TLR rate in the Stellarex arm = 5.9% vs. 16.7% in the PTA arm 2. Data derived f

  18. Slide 18: Consistent Patency Rates Observed across 3 Studies

    89.0% 89.5% 86.5% ILLUMENATE EU RCT N=222 ILLUMENATE FIH N=50 ILLUMENATE Global Interim Data N=220 Consistent Patency Rates Observed across 3 separate studies with Stellarex Kaplan-Meier estimates at day 365 shown 1. H. Schroeder et al. Catheter Cardiovasc Interv. 86:278-286 (2015). 2. P. Krishnan o

  19. Slide 19: Data in Context: 12-Month Patency Rates

    89.0% 65.0% 89.8% 66.8% 73.5% 56.8% Stellarex 2 µg/mm PTA IN.PACT Admiral 3.5 µg/mm PTA Lutonix 2 µg/mm PTA Data in Context with Core Lab* Adjudicated 12-Month Patency Rates ILLUMENATE EU-RCT IN.PACT SFA1 LEVANT 2 2 1. Tepe G. Oral presentation . Charing Cross. April 5–8, 2014. London, UK, 2014. 2.

  20. Slide 20: Data in Context: Clinically-Driven TLR at 12 Months

    5.9% 16.7% 2.4% 20.6% 12.3% 16.8% Stellarex 2µg/mm PTA IN.PACT Admiral 3.5 µg/mm PTA Lutonix 2µg/mm PTA Data in Context: Clinically-Driven TLR at 12 Months ILLUMENATE EU-RCT IN.PACT SFA1 LEVANT 22 1. Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal a

  21. Slide 21: Conclusions

    Conclusions • This robust randomized study confirms First-in- Human study results • Primary safety and efficacy endpoints met and superiority was demonstrated • Stellarex is a low-dose DCB with consistently positive results – Primary Patency= 89.0% at day 365 – Freedom from CD-TLR= 94.8% at day 365

Spectranetics — Technical Presentation (August 2016) on 6ix